Cargando…
National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points
INTRODUCTION: The National Institute on Aging (NIA) provides funding to academic researchers and small businesses working in the Alzheimer's Disease (AD) and AD‐related dementia (ADRD) fields to help commercialize their products. The NIA uses Small Business Innovation Research (SBIR) awards to...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291195/ https://www.ncbi.nlm.nih.gov/pubmed/34374496 http://dx.doi.org/10.1002/alz.12392 |
_version_ | 1784749088354336768 |
---|---|
author | Ghazarian, Armineh L Haim, Todd Sauma, Samir Katiyar, Pragati |
author_facet | Ghazarian, Armineh L Haim, Todd Sauma, Samir Katiyar, Pragati |
author_sort | Ghazarian, Armineh L |
collection | PubMed |
description | INTRODUCTION: The National Institute on Aging (NIA) provides funding to academic researchers and small businesses working in the Alzheimer's Disease (AD) and AD‐related dementia (ADRD) fields to help commercialize their products. The NIA uses Small Business Innovation Research (SBIR) awards to bridge the funding gap in the diagnostic, therapeutic, and care interventions areas, enabling startups to reach key value inflection points to achieve scientific milestones. METHODS: Only publicly available information is reported. The National Institutes of Health Report Portfolio Online Reporting Tool database and the commercial database Global Data, were used to track the progress of companies that received SBIR or Small Business Technology Transfer (STTR) funding from the NIA. RESULTS: Since 2008, the NIA has awarded $280 million—including $207 million from fiscal year (FY) 2015 to FY 2019—in new small business program awards for AD/ADRD research. DISCUSSION: NIA seed capital and mentoring programs are critical resources to help small businesses reach key value inflection points and advance their research from concept to commercialization. |
format | Online Article Text |
id | pubmed-9291195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92911952022-07-20 National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points Ghazarian, Armineh L Haim, Todd Sauma, Samir Katiyar, Pragati Alzheimers Dement Review Article INTRODUCTION: The National Institute on Aging (NIA) provides funding to academic researchers and small businesses working in the Alzheimer's Disease (AD) and AD‐related dementia (ADRD) fields to help commercialize their products. The NIA uses Small Business Innovation Research (SBIR) awards to bridge the funding gap in the diagnostic, therapeutic, and care interventions areas, enabling startups to reach key value inflection points to achieve scientific milestones. METHODS: Only publicly available information is reported. The National Institutes of Health Report Portfolio Online Reporting Tool database and the commercial database Global Data, were used to track the progress of companies that received SBIR or Small Business Technology Transfer (STTR) funding from the NIA. RESULTS: Since 2008, the NIA has awarded $280 million—including $207 million from fiscal year (FY) 2015 to FY 2019—in new small business program awards for AD/ADRD research. DISCUSSION: NIA seed capital and mentoring programs are critical resources to help small businesses reach key value inflection points and advance their research from concept to commercialization. John Wiley and Sons Inc. 2021-08-10 2022-02 /pmc/articles/PMC9291195/ /pubmed/34374496 http://dx.doi.org/10.1002/alz.12392 Text en © 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Article Ghazarian, Armineh L Haim, Todd Sauma, Samir Katiyar, Pragati National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points |
title | National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points |
title_full | National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points |
title_fullStr | National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points |
title_full_unstemmed | National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points |
title_short | National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points |
title_sort | national institute on aging seed funding enables alzheimer's disease startups to reach key value inflection points |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291195/ https://www.ncbi.nlm.nih.gov/pubmed/34374496 http://dx.doi.org/10.1002/alz.12392 |
work_keys_str_mv | AT ghazarianarminehl nationalinstituteonagingseedfundingenablesalzheimersdiseasestartupstoreachkeyvalueinflectionpoints AT haimtodd nationalinstituteonagingseedfundingenablesalzheimersdiseasestartupstoreachkeyvalueinflectionpoints AT saumasamir nationalinstituteonagingseedfundingenablesalzheimersdiseasestartupstoreachkeyvalueinflectionpoints AT katiyarpragati nationalinstituteonagingseedfundingenablesalzheimersdiseasestartupstoreachkeyvalueinflectionpoints |